Every material Form 8-K Calidi Biotherapeutics, Inc. has filed with the SEC since August 13, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Calidi Biotherapeutics received a notice from NYSE American on September 21, 2026, saying it does not meet the $4.0 million stockholders' equity requirement, as it reported $3.1 million as of June 30, 2026. The company must submit a compliance plan by October 21, 2026, and regain compliance by March 21, 2028, or face delisting proceedings, which raises the risk of delisting for shareholders.
Stockholders' equity was $3.1 million as of June 30, 2026, below the $4.0 million NYSE American requires for companies with net losses in three of four recent fiscal years
Notice received September 21, 2026; plan of compliance due October 21, 2026
Company must regain compliance by March 21, 2028; delisting proceedings begin if no plan is submitted or accepted
Common stock continues to trade as CLDI with a ".BC" designation for noncompliance
On September 17, 2026, Calidi Biotherapeutics agreed to sell 1,025,640 common shares at $1.17 per share in a registered direct offering, which closed September 21, 2026, with gross proceeds of approximately $1.2 million before offering expenses. The company plans to use the net proceeds for working capital and general corporate purposes. The share sale increases the number of shares outstanding, and the company agreed not to issue additional equity for 45 days after closing.
1,025,640 shares sold at $1.17 per share, for gross proceeds of approximately $1.2 million before offering expenses.
Offering closed September 21, 2026; no underwriter or placement agent was engaged, and no underwriting discounts or commissions were paid.
Company agreed not to issue or sell equity or equity-linked securities for 45 days after closing, without consent of holders of more than 50% of the shares sold.
Directors and executive officers agreed to 60-day lock-up agreements, subject to customary exceptions.
Calidi Biotherapeutics reported a second-quarter 2026 net loss attributable to common stockholders of $4.2 million, or $2.94 per share, compared with $5.7 million, or $31.75 per share, a year earlier; per-share figures reflect a 1-for-16 reverse split completed in July 2026. Cash fell to $4.1 million by June 30, 2026, and the company's filing lists the risk that it may not raise sufficient capital, which matters for shareholders.
Net loss attributable to common stockholders was $4.2 million, or $2.94 per share, for Q2 2026, versus $5.7 million, or $31.75 per share, in Q2 2025.
General and administrative expenses were $1.6 million, down from $3.1 million; research and development expenses were $2.6 million, unchanged year over year.
Cash was $4.1 million at June 30, 2026, down from $5.6 million at December 31, 2025.
The FDA gave positive pre-IND feedback on CLD-401, and the company targets first patient dosing in Q1 2027.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Calidi Biotherapeutics, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →